All | Portugal | Poland | p* | |
---|---|---|---|---|
(%) | (%) | (%) | ||
Hemoglobin 10–12 g/dL | 67.3 | 65.8 | 69.5 | N.S. |
Hemoglobin > 12 g/dL | 15.2 | 15.3 | 15.1 | N.S. |
Ferritin ≥200 μg/L | 84.4 | 82.9 | 86.6 | N.S. |
Ferritin ≥800 μg/L | 24.0 | 15.8 | 35.6 | < 0.001 |
TSAT ≥20% | 81.5 | 76.3 | 88.8 | < 0.001 |
TSAT ≥50% | 9.4 | 5.7 | 14.6 | < 0.001 |
Treatment with ESA | 76 | 78 | 74 | 0.056 |
Type of ESA | N.S. | |||
Darbepoietin | 24 | 22 | 26 | |
Epoetin beta | 76 | 78 | 74 | |
Route of ESA administration | < 0.001 | |||
Intravenous | 64.5 | 99.8 | 11.5 | |
Subcutaneous | 35.5 | 0.2 | 88.5 | |
ESA administration, frequency | < 0.001 | |||
No ESA | 23.6 | 21.7 | 26.3 | |
Every other week | 0.4 | 0.7 | 0 | |
Once per week | 15.0 | 2.1 | 33.2 | |
Twice per week | 15.9 | 11.1 | 22.6 | |
Three times per week | 45.1 | 64.5 | 18.0 | |
Dialysis modality | < 0.001 | |||
HDF | 46.6 | 91.4 | 0 | |
HD | 53.4 | 8.6 | 100 | |
spKt/V > 1.2 | 97.3 | 98.5 | 95.6 | 0.003 |
URR ≥ 70% | 90.8 | 95.4 | 84.4 | < 0.001 |
Treatment time ≥ 12 h/week | 93.8 | 94.0 | 93.6 | N.S. |
Prescribed Qb ≥ 300 mL/min | 94.1 | 97.4 | 89.4 | < 0.001 |
Treated blood volume ≥ 1 L/kg body weight | 90.0 | 95.7 | 81.9 | < 0.001 |
CVC (%) | 16.5 | 14.5 | 19.3 | 0.026 |
AV Fistula (%) | 76.8 | 77.1 | 76.4 | N.S. |
S-Albumin ≥35 g/L | 89.7 | 95.4 | 81.8 | < 0.001 |
Charlson comorbidity index | < 0.001 | |||
< 7 | 44.5 | 39.1 | 52.1 | |
7–12 | 51.9 | 56.7 | 45.2 | |
> 12 | 3.6 | 4.3 | 2.7 | |
Diabetes mellitus | 26 | 30 | 25 | N.S. |
Phosphorus ≤5.5 mg/dL | 82.0 | 87.5 | 74.2 | < 0.001 |
Calcium ≤10.2 mg/dL | 98.1 | 98.0 | 98.2 | N.S. |
PTH 150–600 pg/mL | 53.9 | 52.1 | 56.4 | N.S. |